Ad-hoc | 25 July 2007 07:41
STRATEC Biomedical Systems AG / Half Year Results/Preliminary Results Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- STRATEC achieves sales and earnings growth in first half of FY 2007 Birkenfeld, July 25, 2007 The Board of Management of STRATEC Biomedical Systems AG, which is listed in the Prime Standard, hereby announces the preliminary unaudited consolidated figures of the consolidated STRATEC Group for the first half of the 2007 financial year as of June 30, 2007 pursuant to IFRS (International Financial Reporting Standards) and in accordance with Section 15 of the German Securities Trading Act (WpHG).Key Figures (EUR 000s) 01.01.- 06.30.2007 01.01.- 06.30.2006 Change Sales 34,098 32,672 + 4.4% Gross performance 34,625 32,501 + 6.5% EBITDA 6,993 5,582 + 25.3% EBIT 5,897 4,901 + 20.3% EBT 5,907 4,832 + 22.2% Consolidated net income 4,185 3,548 + 18.0% Earnings per share (EUR) 0.37 0.32 + 15.6%The consolidated STRATEC Group had a total workforce of 256, including personnel provided by a temporary employment agency, as of June 30, 2007 (previous year: 210). --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: Due to the conversion of the working processes involved in the compilation of our interim reports in English and German, the publication of the interim report for the first half of the 2007 financial year will be postponed by several days. The extensive interim report will be available for downloading from our internet site from around 3.00 p.m. on August 17, 2007. The extensive 'Interim Report as of September 30, 2007' will be available for downloading from our internet site from around 3.00 p.m. on November 15, 2007. About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and on other exchanges. The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical Systems AG and its subsidiaries STRATEC Biomedical Inc., STRATEC NewGen GmbH, Robion AG and Sanguin International Ltd., as well as Sanguin International Inc., a subsidiary of Sanguin International Ltd. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 (0)7082 7916 190 Fax: +49 (0)7082 7916 999 E-mail: ir@stratec-biomedical.de DGAP 25.07.2007 ---------------------------------------------------------------------- Language: English Issuer: STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: info@stratec-biomedical.de Internet: www.stratec-biomedical.de ISIN: DE0007289001 WKN: 728900 Indices: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Stuttgart, München, Düsseldorf End of News DGAP News-Service ---------------------------------------------------------------------------